Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 3/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.34 |
| ▸ | TYK2 | P29597 | 2/20 | 0.34 |
| ▸ | JAK3 | P52333 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19082952 | 0.86 | JAK2 (0.32) | KDRJAK2JAK3ADORA2AADORA1 | |
| SCHEMBL19082951 | 0.83 | JAK2 (0.32) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL17017077 | 0.80 | PKM (0.33) | PKMNPY5RCHRM2MEN1CHRM4 | |
| SCHEMBL29829258 | 0.80 | PKM (0.33) | PKMNPY5RCHRM2MEN1CHRM4 | |
| SCHEMBL19082946 | 0.80 | ADORA2A (0.40) | JAK2JAK1TYK2JAK3PKM | |
| SCHEMBL19082963 | 0.77 | NPY5R (0.49) | KDREGFRPDGFRBJAK2JAK1 | |
| SCHEMBL19082955 | 0.74 | PRKCI (0.33) | KDRJAK2JAK3ADORA2AADORA1 | |
| SCHEMBL19082960 | 0.72 | NUDT1 (0.36) | KDRJAK2JAK3ADORA2AADORA1 | |
| SCHEMBL19082948 | 0.70 | PRKCI (0.36) | KDRJAK2JAK1TYK2JAK3 | |
| SCHEMBL19082953 | 0.69 | NUDT1 (0.34) | KDRJAK2JAK1JAK3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190704-A1 | COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | Mitokinin, LLC (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190704-A1 | COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | NLN, HAGH, MT-ND2 | KDR 4772/4885EGFR 4095/4885PDGFRB 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.